Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 114 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lipodystrophy Clear all
Completed Phase 2 Interventional Results available

Cholic Acid for Hepatic Steatosis in Lipodystrophy

NCT00457639
View directory record Official record
Conditions
Hepatic Steatosis
Interventions
Cholic Acid
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 4 Interventional Results available

Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

NCT00135356
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome
Interventions
Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Honolulu, Hawaii • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2010 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

NCT02639286
View directory record Official record
Conditions
Lipodystrophy
Interventions
ISIS 304801, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 4 Interventional

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

NCT00005764
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 6, 2026, 7:43 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

NCT01724580
View directory record Official record
Conditions
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
Interventions
Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Leptin to Treat Lipodystrophy

NCT00025883
View directory record Official record
Conditions
Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340
View directory record Official record
Conditions
HIV-associated Lipodystrophy Syndrome
Interventions
GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Sep 6, 2026, 7:43 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

NCT03848182
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, TT vaccine booster
Drug · Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

NCT00656851
View directory record Official record
Conditions
HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy, The Metabolic Syndrome
Interventions
Pioglitazone, Exercise Training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
28 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 3 Interventional

TH9507 in Patients With HIV-Associated Lipodystrophy

NCT00123253
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
TH9507
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Not applicable Interventional

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

NCT00028314
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Wasting Disease
Interventions
Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)

NCT01023620
View directory record Official record
Conditions
HIV Infections
Interventions
Pioglitazone, Observation
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

NCT02684591
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, HIV
Interventions
Aramchol, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 6, 2026, 7:43 AM EDT
Terminated Phase 4 Interventional Results available

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

NCT01194856
View directory record Official record
Conditions
HIV Infection, Mitochondrial Dysfunction
Interventions
Atazanavir/ritonavir, Efavirenz
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 6, 2026, 7:43 AM EDT
Recruiting Phase 3 Interventional

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

NCT06679270
View directory record Official record
Conditions
Familial Partial Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Boca Raton, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

NCT00608023
View directory record Official record
Conditions
Lipodystrophy, HIV Infections
Interventions
Tesamorelin, Placebo for Tesamorelin
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Indio, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 6, 2026, 7:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Metabolism and Body Shape of Healthy Children and Children With Chronic Infections

NCT00001142
View directory record Official record
Conditions
HIV Infections, Healthy, Hyperlipidemia, Lipodystrophy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 4 Interventional

Yoga for the Management of HIV-Metabolic Syndromes

NCT00627380
View directory record Official record
Conditions
HIV Infections, HIV Metabolic Cardiovascular Syndrome, HIV Lipodystrophy, HIV Metabolic Syndromes, Hypertension
Interventions
Yoga lifestyle intervention, Standard of care
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 25, 2010 · Synced Sep 6, 2026, 7:43 AM EDT
Not listed Not applicable Interventional

Pilot Study of Raltegravir Lipodystrophy IISP

NCT01164605
View directory record Official record
Conditions
HIV Infection
Interventions
Raltegravir
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

NCT00140244
View directory record Official record
Conditions
HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions
r-metHuLeptin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Approaches to HAART-Induced Lipodystrophy

NCT00461552
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Leptin, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
14 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

NCT03514420
View directory record Official record
Conditions
Familial Partial Lipodystrophy
Interventions
AKCEA-ANGPTL3-LRx
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia

NCT00246376
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia, Hypertriglyceridemia, Insulin Resistance, Atherosclerosis
Interventions
Diet, Exercise, Niacin, Fenofibrate, Placebos
Behavioral · Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 6, 2026, 7:43 AM EDT
Completed Not applicable Interventional Results available

Effects of Short-term Growth Hormone in HIV-infected Patients

NCT00795210
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
Growth hormone, Growth Hormone Releasing Hormone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 6, 2026, 7:43 AM EDT